Hycor Biomedical

Hycor Biomedical specializes in innovative diagnostic solutions for allergy testing, primarily through its advanced NOVEOS® system designed for rapid and accurate allergy diagnostics. Founded in 1981 and headquartered in Garden Grove, US, Hycor Biomedical LLC focuses on allergy testing solutions. The company underwent a strategic shift when, in February 2013, Linden Capital Partners sold its urinalysis business to One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital. HYCOR Biomedical LLC specializes in diagnostic solutions for allergy testing, primarily through its flagship product, the NOVEOS® system.

This sophisticated platform is designed to enhance laboratory efficiency by providing accurate and rapid testing for specific IgE allergens, which are critical for diagnosing allergic conditions. The system employs advanced microparticle testing technology and interference avoidance techniques to ensure high-quality results. The NOVEOS® system is targeted at healthcare professionals, including allergists and clinical laboratories, serving a diverse client base across regions such as North America, Europe, and Asia. Alongside the NOVEOS® system, HYCOR offers the HYTEC Multiple Real-Time PCR Kit, expanding its portfolio to cater to various diagnostic needs in allergy and immunology.

HYCOR Biomedical LLC generates revenue primarily through the sale of its diagnostic testing systems and associated assays. The company engages in B2B transactions, partnering with healthcare providers and laboratories that require comprehensive allergy testing solutions. Revenue is derived from both direct sales of the NOVEOS® system and the sale of consumables and assays, which are necessary for performing tests. As part of its business model, HYCOR may provide service agreements that ensure ongoing support and maintenance for its equipment, fostering long-term relationships with clients.

Additionally, the company may offer subscription-based models for access to its testing platforms and educational resources, enhancing customer engagement and satisfaction. Hycor Biomedical is actively working on the development of new products designed to enhance its diagnostic capabilities in allergy testing. The company is also exploring expansion into new markets, specifically targeting increased penetration in Europe and Asia by 2025. The financial resources from the recent deal in February 2013 will be utilized to support these initiatives, focusing on product development and market expansion strategies.